Susquehanna International Group, LLP Autolus Therapeutics PLC Call Options Transaction History

Susquehanna International Group, LLP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q2 2024 Aug 15, 2024	SELL	$3.33 - $5.68 $201,798 - $344,208	-60,600 Reduced 72.92%	22,500 $78,000
Q1 2024 May 07, 2024	SELL	$5.39 - $7.29 $90,013 - $121,743	-16,700 Reduced 16.73%	83,100 $530,000
Q4 2023 Feb 14, 2024	SELL	$2.13 - $6.63 $90,525 - $281,775	-42,500 Reduced 29.87%	99,800 $642,000
Q3 2023 Nov 14, 2023	BUY	$2.32 - $3.36 $115,535 - $167,328	49,800 Added 53.84%	142,300 $331,000
Q2 2023 Aug 11, 2023	BUY	$1.64 - $3.21 $151,700 - $296,925	92,500 New	92,500 $220,000
Q4 2022 Feb 14, 2023	BUY	$1.74 - $3.27 $27,492 - $51,666	15,800 New	15,800 $30,000
Q2 2022 Aug 15, 2022	SELL	$2.04 - $4.68 $68,748 - $157,716	-33,700 Reduced 76.24%	10,500 $30,000
Q1 2022 May 16, 2022	SELL	$3.52 - $5.46 $16,896 - $26,208	-4,800 Reduced 9.8%	44,200 $184,000
Q4 2021 Feb 14, 2022	SELL	$5.1 - $7.0 $12,750 - $17,500	-2,500 Reduced 4.85%	49,000 $254,000
Q3 2021 Nov 15, 2021	BUY	$5.32 - $7.37 $273,980 - $379,555	51,500 New	51,500 $337,000

104

163M

2.8K

13.4K

Ticker AUTL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 90,909,800
Market Cap $272M
Description
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.